Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial - The Lancet Oncology

A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma

Full article: Efficacy and safety of the combined use of ipilimumab and nivolumab for melanoma patients with brain metastases: a systematic review and meta-analysis

Nivolumab With Ipilimumab May Negate Need for Whole Brain Radiotherapy in Melanoma With Brain Metastases - Cancer Therapy Advisor

Frontiers Successful Treatment of Unresectable Advanced Melanoma by Administration of Nivolumab With Ipilimumab Before Primary Tumor Resection

Figure 3 from Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

The Efficacy and Safety of Immune Checkpoint Inhibitors in Treating Melanoma

Intratumoural immunotherapies for unresectable and metastatic melanoma: current status and future perspectives